The Use of Superparamagnetic Iron Oxide Nanoparticles to Assess Cardiac Inflammation

被引：6

作者：

Stirrat C.G. ^{[1
]}

Newby D.E. ^{[1
]}

Robson J.M.J. ^{[1
]}

Jansen M.A. ^{[1
]}

机构：

[1] British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, EH16 4SB, Su 305 Chancellor's Building

来源：

Current Cardiovascular Imaging Reports | 2014年 / 7卷 / 5期

基金：

英国医学研究理事会;

关键词：

Cardiac; Inflammation; Iron oxide nanoparticles; Molecular imaging; MRI;

D O I：

10.1007/s12410-014-9263-3

中图分类号：

学科分类号：

摘要：

Superparamagnetic iron oxide-based contrast agents enhance and complement in vivo magnetic resonance imaging (MRI) by shortening T2 and T2* relaxation times. They are able to highlight areas of cellular inflammation, being detected and engulfed by cells of the reticuloendothelial system, and can be targeted to specific cellular processes or subtypes using antibody or ligand labeling. These agents have been used preclinically for the assessment of cardiac transplant rejection, cardiomyocyte apoptosis, myocardial infarction, myocarditis, and stem and endothelial cell imaging, with clinical applications now emerging. We here review recent studies using iron oxide particles to image cardiac inflammation, and highlight the potential of these agents for future clinical and research applications. © 2014 Springer Science+Business Media New York.

引用

页码：1 / 8

页数：7

共 45 条

[1]

Cooper L.T., Baughman K.L., Feldman A.M., Frustaci A., Jessup M., Kuhl U., Et al., The role of endomyocardial biopsy in the management of cardiovascular disease. A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology, J Am Coll Cardiol, 50, pp. 1914-1931, (2007)

[2]

Wang Y.-X.J., Hussain S.M., Krestin G.P., Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging, Eur Radiol, 11, pp. 2319-2331, (2001)

[3]

Wang Y.-X.J., Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application, Quant Imaging Med Surg, 1, pp. 35-40, (2011)

[4]

Allkemper T., Bremer C., Matuszewski L., Ebert W., Reimer P., Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits, Radiology, 223, pp. 432-438, (2002)

[5]

Mandeville J.B., Moore J., Chesler D.A., Garrido L., Weissleder R., Weisskoff R.M., Dynamic liver imaging with iron oxide agents: effects of size and biodistribution on contrast, Magn Reson Med, 37, pp. 885-890, (1997)

[6]

Hahn P.F., Stark D.D., Lewis J.M., Saini S., Elizondo G., Weissleder R., Et al., First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging, Radiology, 175, pp. 695-700, (1990)

[7]

Saini S., Stark D.D., Wittenberg J., Brady T.J., Ferrucci J.T., Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system, Radiology, 162, pp. 211-216, (1987)

[8]

Rogers J.M., Lewis J., Josephson L., Visualization of superior mesenteric lymph nodes by the combined oral and intravenous administration of the ultrasmall superparamagnetic iron oxide, AMI-227, Magn Reson Imaging, 12, pp. 1161-1165, (1994)

[9]

Zimmer C., Weissleder R., O'Connor D., LaPointe L., Brady T.J., Enochs W.S., Cerebral iron oxide distribution: in vivo mapping with MR imaging, Radiology, 196, pp. 521-527, (1995)

[10]

Canet E., Revel D., Forrat R., Baldy-Porcher C., de Lorgeril M., Sebbag L., Et al., Superparamagnetic iron oxide particles and positive enhancement for myocardial perfusion studies assessed by subsecond T1-weighted MRI, Magn Reson Imaging, 11, pp. 1139-1145, (1993)

← 1 2 3 4 5 →